Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioFreedom Stent in High Bleeding Risk Patients
NCT02843633Active, not recruiting
- Sponsor
- Biosensors International Group, Ltd.
- Start
- Feb 2017
- Primary completion
- Oct 2018
- Countries
- 7
01
Overview
Open-label, single-arm trial in coronary artery disease (CAD) and acute coronary syndrome (ACS), sponsored by Biosensors International Group, Ltd. Primary endpoints: Composite of cardiac death and myocardial infarction at 12 months and Incidence of clinically driven target lesion revascularization at 12 months. Started Feb 2017; status: active, not recruiting.
02
Conditions
coronary artery disease (CAD)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02843633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843633.